| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
NeuroPace, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$7.10 |
| 52 Week High | US$18.15 |
| 52 Week Low | US$4.40 |
| Beta | 1.81 |
| 11 Month Change | -10.80% |
| 3 Month Change | -10.69% |
| 1 Year Change | 51.06% |
| 33 Year Change | -65.14% |
| 5 Year Change | n/a |
| Change since IPO | -71.55% |
Recent News & Updates
Recent updates
NeuroPace, Inc. (NASDAQ:NPCE) Screens Well But There Might Be A Catch
Aug 03
Is NeuroPace (NASDAQ:NPCE) Weighed On By Its Debt Load?
Apr 12NeuroPace: Picking Up The Pace
Feb 25Why Investors Shouldn't Be Surprised By NeuroPace, Inc.'s (NASDAQ:NPCE) 58% Share Price Surge
Jan 22NeuroPace, Inc. (NASDAQ:NPCE) Stock Rockets 39% But Many Are Still Ignoring The Company
Apr 17NeuroPace announces U.S. distribution agreement with DIXI Medical
Aug 11NeuroPace EPS misses by $32.45, beats on revenue; issues guidance
Jun 03Shareholder Returns
| NPCE | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 2.9% | 3.9% | 4.9% |
| 1Y | 51.1% | 11.2% | 25.6% |
Return vs Industry: NPCE exceeded the US Medical Equipment industry which returned 10.3% over the past year.
Return vs Market: NPCE exceeded the US Market which returned 24.7% over the past year.
Price Volatility
| NPCE volatility | |
|---|---|
| NPCE Average Weekly Movement | 9.5% |
| Medical Equipment Industry Average Movement | 8.3% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.0% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: NPCE's share price has been volatile over the past 3 months.
Volatility Over Time: NPCE's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1997 | 179 | Joel Becker | www.neuropace.com |
NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.
NeuroPace, Inc. Fundamentals Summary
| NPCE fundamental statistics | |
|---|---|
| Market cap | US$200.58m |
| Earnings (TTM) | -US$29.90m |
| Revenue (TTM) | US$71.82m |
2.9x
P/S Ratio-6.9x
P/E RatioIs NPCE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NPCE income statement (TTM) | |
|---|---|
| Revenue | US$71.82m |
| Cost of Revenue | US$18.56m |
| Gross Profit | US$53.26m |
| Other Expenses | US$83.15m |
| Earnings | -US$29.90m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.02 |
| Gross Margin | 74.15% |
| Net Profit Margin | -41.63% |
| Debt/Equity Ratio | 597.0% |
How did NPCE perform over the long term?
See historical performance and comparison